The Drug Trend Report

Programs & Services
Innovative programs designed to tackle challenges payors face today
Competition should meaningfully reduce drug costs and bring significant savings for payors
Robust pipeline is expected to bring significant savings in the autoimmune category
Indications for Janus kinase inhibitors are expanding, as are safety concerns